

AMENDMENTS TO THE SPECIFICATION

Please insert the accompanying Sequence Listing at the end of the specification.

Please replace paragraph 4 on page 8 with the following amended paragraph:

A chart comprising SEQ ID NO: 1 and its complementary sequence as well as the encoded amino acids (SEQ ID NO:6) are depicted below. ~~SEQ ID NO: 1 is,~~ showing the nucleic acid and amino acid sequence of the heavy chain's variable region of the antibody of the invention.

Please replace paragraph 2 on page 9 with the following amended paragraph:

Further, a chart comprising SEQ ID NO: 2 and its complementary sequence as well as the encoded amino acids (SEQ ID NO:7) are depicted below. ~~SEQ ID NO: 2 is,~~ showing the nucleic acid and amino acid sequence of the light chain's variable region of the antibody of the invention.

Please replace paragraph 2 on page 29 with the following amended paragraph:

Generation of TLR2ECD specific antibodies and ELISA. A cDNA fragment encoding the N-terminal 587 amino acids of mTLR2⁴¹ was amplified from a RAW264.7 cDNA library (advantage kit, BD Clontech, Heidelberg, Gennany). The murine TLR2ECD was fused to a C-terminal thrombin cleavage site followed by a human IgGFcγ moiety. The murine TLR2ECD protein was purified upon overexpression in HEK293 cells and thrombin digestion. A *TLR2*^{-/-} mouse was immunized by intraperitoneal (i. p.) injection of 50 μg of TLR2ECD and 10 nmol of a thioated DNA oligonucleotide (5'-TCCATGACGTTCTGA-3', Tib Molbiol, Berlin, Gennany) (SEQ ID NO: 5) for three times within eight weeks. Its splenocytes were fused with murine P3X

cells and hybridomas were selected⁴². MAb specificities for TLR2ECD, as well as cyto- and chemokine concentrations in cell supernatants or murine sera (see below) were analyzed by ELISA (R&D systems, Minneapolis, Minnesota).